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Background: Antibiotic allergy labels are associated with sub-optimal prescribing patterns and poorer clinical outcomes
in non-cancer populations, but the effect of labelling on antimicrobial usage in patients with cancer is unknown.
Findings: A retrospective review of hospitalized patients admitted to the Peter MacCallum Cancer Centre (2010-2012)
identified 23 % of cancer patients (n = 198) with an antimicrobial allergy label (AA). Comparison of those with an
antimicrobial allergy label to those without demonstrated increased antibiotic use per admission (3 vs. 2, p = 0.01),
increased fluoroquinolone use (11 % vs. 6 %, p < 0.05), increased antibiotic course duration (15 vs. 13 days, p = 0.09),
higher readmission rates (53 % vs. 28 %, p < 0.001) and poorer concordance with prescribing guidelines (47 % vs. 91 %,
p < 0.001). Patients in the AA group on multivariate analysis had a higher number of antibiotics employed, longer
duration of antibiotic therapy and higher rate of readmission.
Conclusions: Antimicrobial usage, including the use of restricted antibiotics, is higher in patients with cancer.
Antibiotic de-labelling strategies in cancer patients must be evaluated to aid antimicrobial stewardship initiatives.
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Despite 10-20 % of patients reporting an antimicrobial
allergy, less than 1 % of patients test positive on skin-
prick-testing/intradermal testing (SPT/IDT) [1–3]. Recent
studies in mixed populations demonstrate increased anti-
microbial use, poorer patient outcomes and development
of microbiological resistance in those with an anti-
biotic allergy label [3–5]. However, the impact of anti-
microbial allergy labels on cancer patients and
antimicrobial usage has not yet been defined. The ob-
jectives of our study were to: (i) determine the preva-
lence of antimicrobial allergy labels in patients with
cancer, (ii) provide a description of reported antibiotic
allergies and re-challenge history, and (iii) to describe
the impacts of an antimicrobial allergy label on anti-
microbial choice, usage and clinical outcomes.* Correspondence: jason.trubiano@petermac.org
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Study design, setting and population
Peter MacCallum Cancer Centre (PMCC) is a tertiary
referral center treating all cancer patients. This was a
single center retrospective review of oncology and
hematology patients admitted to PMCC between June
2010 and July 2012 with a coded infective diagnosis
according to the International Classification of Disease-
10-AM. Study inclusion criteria were: (i) coded infective
diagnosis, (ii) receipt of an antimicrobial agent for treat-
ment of infection, and (iii) inpatient admission > 24 h. The
study was approved by the PMCC ethics- committee.
Using medical and pharmacy records, patients were di-
vided into two study groups: (i) those with an antimicrobial
allergy label (AA), reporting an allergy or adverse drug reac-
tion to an antimicrobial and (ii) those without no anti-
microbial allergy label (NAA). The AA group included
patients with Type A and/or Type B antimicrobial adverse
drug reactions (see Definitions below). The pharmacy re-
cords and allergy particulars are updated by a dedicated
ward pharmacist for all hospital admissions.
For all patients, demographics characteristics, infective
diagnosis, age-adjusted Charlson Comorbidity Index (CCI),
[6] mental health and malignancy history was recorded.al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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initial and subsequent admissions during the study period
was recorded: agent(s), doses, frequency, route of administra-
tion and duration. Patient re-admission rate and outcomes
(inpatient 30-day, and 60-day mortality) were captured.
For the AA patients additional information obtained in-
cluded; allergy description, reporting clinician, re-challenge
history during study period, de-sensitization history during
study period and allergy/immunologist specialist referral.
Patients were excluded if antibiotic administration records
were incomplete.
Definitions
AA labels were classified as either Type A or Type B
based upon the following criteria:
 Type A: Non-immune mediated adverse drug
reactions consistent with a known drug side effect
(e.g. gastrointestinal upset).
 Type B: Reactions consistent with an IgE-mediated
(e.g. angioedema, anaphylaxis or urticaria) OR T-cell
mediated (e.g. serum sickness, antibiotic induced
hemolytic anemia, maculopapular eruption or
Severe Cutaneous Adverse Reaction) reaction.
For the purposes of this study, concordance with pre-
scribing guidelines was determined by comparing antibiotic
choice with first-line recommendations provided by the
Australian Therapeutic Guidelines (Antibiotic) and national
guidelines for management of neutropenic fever [7, 8].
An antibiotic course was defined as > 24 h of antibiotic
therapy targeting an infective diagnosis. An antimicrobial
allergy manifestation was defined as any reported allergy or
adverse drug reaction (Type A or B) to an antimicrobial,
listed in the allergy box of medical record.
Statistical analysis
Statistical analyses, including multivariate analysis, were
performed using Stata 12.0 (Statacorp, Texas). Clinical
outcomes were compared between the AA and NAA
groups. Categorical variables were compared using the
chi-squared test and continuous variables compared
using the Wilcoxon rank sum test. A P-value of <0.05
was deemed statistically significant.
Results
Patient demographics
198 patients with at least one infective episode were identi-
fied during the study period. Of these, 45 (23 %) had an
antimicrobial allergy label (AA) and 153 (77 %) had no label
(NAA). The groups were comparable with respect to
age, sex, Charlson Comorbidity Index, mental health
history, ICU-admission rate and mortality /30-day/60-day
(Table 1).Allergy labels & manifestations
In the AA patients, 62 allergy manifestations were re-
corded. Ten of the 62 allergy manifestations (16 %) were
Type A adverse drug reactions (gastrointestinal 5; other
5). Of the Type B allergies (52/62; 84 %), IgE and T-cell
mediated manifestations were reported in 8/52 (15 %)
and 44/52 (85 %) respectively. Antibiotic allergies were
most commonly attributed to beta-lactams (65 %),
followed by sulfonamides (11 %), glycopeptides (6 %),
fluroquinolones (5 %), macrolides (5 %) and tetracyclines
(2 %). More specifically, the causal antibiotic(s) included
penicillin/aminopenicillins 23/62 (46 %), piperacillin-
tazobactam 9/62 (14 %), trimethoprim/sulfamethoxazole
7/62 (11 %), vancomycin 4/62 (7 %), flucloxacillin 3/62
(5 %), ciprofloxacin 3/62 (5 %), cephalexin 2/62 (3 %), cefta-
zidimine 1/62 (2 %), cefepime 1/62 (2 %), cefuroxime 1/62
(2), dapsone 2/62 (3 %), metronidazole 2/62 (3 %), roxithro-
mycin 2/62 (3 %), and doxycycline 1 (2 %).
Re-challenge with the offending antimicrobial was
more likely if the allergy label was non-IgE mediated
compared with IgE mediated (p = 0.024). Six of 44 pa-
tients with a rash (14 %) and 3/10 (30 %) with a Type A
history were re-challenged. No formal SPT was recorded
for the AA group. The health professional reporting the
antimicrobial allergy was unknown in 37/62 (60 %),
physician in 19/62 (30 %), pharmacist 3/62 (5 %), sur-
geon 2/62 (3 %) and general practitioner 1/62 (2 %).
Antimicrobial usage & multivariate analysis
The median number of antibiotics used per admission
was significantly higher in the AA group compared with
the NAA group (3 vs. 2, p = 0.01), with a trend toward
longer antibiotic duration (15 days vs. 13 days, p =0.09).
Concordance with 1st line therapy occurred less fre-
quently in the AA group (21/45; 47 % vs. 139/153; 91 %,
p < 0.001). There was no difference in 30-day or 60-day
mortality and LOS in the two groups. The median num-
ber of readmissions and/or readmissions with an infec-
tious disease diagnosis requiring antimicrobial therapy
was higher for the AA group (Table 1). For both first ad-
mission and re-admissions, ciprofloxacin (11.7 % vs.
4.7 %, p < 0.001), meropenem (12.1 % vs. 9.1 %, p = 0.21)
and cefepime (9.3 % vs. 1.2 %, p < 0.001) use as percentage
of total antibiotic courses was higher in AA group com-
pared to NAA group. There was no difference in vanco-
mycin use between the 2 groups (15 % vs. 15 %, p = 0.9).
The percentage of total antibiotic courses per antimicro-
bial class for the AA and NAA groups is demonstrated in
Fig. 1.
On multivariate logistic regression adjusting for age
group, inpatient surgery, sex, ICU admission and LOS
there was a higher readmission rate with an infective diag-
nosis (OR 3.27 95%CI 1.55-6.88, p = 0.002) and overall re-
admission rate (OR 1.99, 95%CI 0.95-4.15, p = 0.069) in
Table 1 Characteristics of AA and NAA groups
Patient characteristics No label Label p-
value(N = 153) (N = 45)
n (%) n (%)
Age (years)
Median (range) 65 (22-92) 64 (22-90) 0.48
Charlson Comorbidity Indexa
Median (range) 4 (2-12) 4 (2-10) 0.36
Sex
Male 86 (56) 20 (44) 0.16
Mental health historyb
Yes 24 (16) 7 (16) 0.98
Treating unit
Hematology 93 (61) 27 (60) 0.85
Medical Oncology 44 (29) 12(27)
Surgical Oncology 30 (20) 8 (18) 0.51
Malignancy type
Leukemia 29 (19) 13 (29)
Lymphoma 60 (39) 17 (38)
Solid Malignancy 27 (18) 6 (13)
Multiple myeloma
Inpatient surgery
Yes 26 (17) 9 (20) 0.87
ICU admission
Yes 39 (26) 12 (27) 0.87
Infectious episodes
Febrile neutropenia 70 (21) 24 (24) 0.54
Gram negative bacteremia 31 (9) 12 (12)
Gram positive bacteremia 25 (8) 6 (6)
Polymicrobial bacteremia 11 (3) 2 (2)
Skin and soft tissue infection 16 (5) 10 (10)
Pneumonia 19 (6) 8 (8)
Invasive fungal infection 18 (6) 4 (4)
Intra-abdominal collection 13 (4) 3 (3)
Mortality (all-cause)
30 day 6 (3.9) 1(2.2) 0.59
60 day 10 (6.5) 2 (4.5) 0.89
Length of Stay
Median (range) 19 (2-151) 23 (3-157) 0.4618
Readmissions
Median (range) 2 (0-11) 3.5 (1-17) 0.02
Readmission with an infectious diagnosis
Yes 42 (27.5) 24 (53.3) 0.01
a Age-adjusted Charlson Comorbidity Index [6]
b Mental Health History: Recorded from patient history
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antibiotics employed (regression coefficient 0.57, 95%CI
0.09-1.06, p = 0.021) and duration of antibiotic therapy
(regression coefficient 6.70, 95%CI 0.84-12.5, p = 0.03) was
higher in the AA group.Discussion
In a cohort of hospitalized patients with cancer and an
inter-current infection, we identified on multivariate
analysis significant impacts of antimicrobial allergy la-
belling, including (i) increased total number of admin-
istered antibiotics, (ii) increased antibiotic duration
and (iii) higher re-admission rates. Previously, the
prevalence of allergy labelling in non-surgical patients
has been estimated to be 11 %, with increased anti-
biotic usage, length-of-stay and mortality noted in the
allergy label group [4]. Penicillin allergy labels in
mixed patient populations have been associated with
increased antimicrobial usage [5]. However, our study
is the first to identify a high rate of antimicrobial allergy
labels (23 %) in a cancer patient cohort with demonstrable
effects on antimicrobial prescribing.
Increasing rates of multi-drug resistant organisms
are observed amongst cancer patients, along with in-
creasing fluoroquinolone and carbapenem use [9–11].
We demonstrated during the study period an increase
in fluoroquinolone and carbapenem use in our AA
group. Improving pathways to ‘de-labeling’ may re-
duce the unwarranted use of these agents [3, 12]. The
high rate of rash manifestations (71 %), yet low rate of
direct re-challenge in this population suggests a need
for more comprehensive evaluation. For many ‘rash’
manifestations, the reported exanthem is frequently
mild, not directly related to antimicrobial agents [13].
Enhanced education and introduction of programs to
assess allergy status will reduce the number of anti-
microbial allergy labels and may allow these patients
to be safely re-challenged. Remaining IgE-mediated
manifestations should be further investigated with
SPT/IDT as part of a de-labeling program [3, 14, 15].
The main limitation of this study is the retrospect-
ive study design that restricted the ability to clarify
the nature of specific antimicrobial allergy labels.
However, dedicated ward pharmacist roles during the
study period enabled capture of data upon hospital
admission, and we believe our data to be valid. Other
limitations include small study numbers and hetero-
geneity of cancer populations. The use of ICD-10-
AM coding data to identify patients is likely to have
underestimated the number of infectious episodes.
However, this would be applicable to both of our
study groups and therefore unlikely to affect the
studied outcomes.
Fig. 1 The percentage of total antibiotic courses (all admissions during study period) per antimicrobial class for antimicrobial allergy (AA) and no
antimicrobial allergy (NAA) groups. Abbreviations: AA, antimicrobial allergy group; NAA, no antimicrobial allergy group. *P value < 0.05
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In summary, almost one quarter of patients admitted to
our centre with cancer and an infection had an anti-
microbial allergy label. Antibiotic administration rates
were higher and duration longer in the AA group. The
potential benefits of antimicrobial allergy ‘de-labeling’
strategies must be evaluated prospectively in at-risk cancer
populations to aid antimicrobial stewardship programs
and prevent resistance generation.
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